

# Reinhold Munker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1282958/publications.pdf>

Version: 2024-02-01

26  
papers

647  
citations

687363

13  
h-index

580821

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1376  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
2	Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. <i>European Journal of Haematology</i> , 2019, 102, 157-162.	2.2	73
3	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
4	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
5	Survival of patients with mixed phenotype acute leukemias: A large population-based study. <i>Leukemia Research</i> , 2015, 39, 606-616.	0.8	47
6	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	3.5	43
7	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€“Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
8	Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1024-1029.	2.0	39
9	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 2134-2140.	3.5	33
10	Insurance Status and Other Non-biological Factors Predict Outcomes in Acute Myelogenous Leukemia: Analysis of Data from the National Cancer Database. <i>Anticancer Research</i> , 2016, 36, 4915-4922.	1.1	29
11	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1056-1064.	2.0	26
12	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
13	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
14	Multiple Myeloma and Other Malignancies: A Pilot Study From the Houston VA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 102-106.	0.4	13
15	Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (<scp>MPAL</scp>): A cancer registry analysis on realâ€“world outcome. <i>American Journal of Hematology</i> , 2020, 95, 1015-1021.	4.1	13
16	Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. <i>Leukemia Research</i> , 2020, 89, 106301.	0.8	11
17	Anti-thymocyte globulin in haematology: Recent developments. <i>Indian Journal of Medical Research</i> , 2019, 150, 221.	1.0	8
18	Tolosa-Hunt Syndrome in Double-Hit Lymphoma. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-4.	0.3	7

#	ARTICLE	IF	CITATIONS
19	The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation. <i>Acta Haematologica</i> , 2016, 135, 146-155.	1.4	7
20	The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2020, 104, 2507-2515.	1.0	5
21	Obstructing Duodenal Diffuse Large B-cell Lymphoma with Peritoneal Lymphomatosis with Exceptional Response to R-CHOP. <i>Cureus</i> , 2019, 11, e4621.	0.5	4
22	Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning. <i>European Journal of Haematology</i> , 2017, 99, 56-59.	2.2	3
23	Progress in multiple myeloma. <i>Indian Journal of Medical Research</i> , 2019, 149, 693.	1.0	3
24	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
25	Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL. <i>EJHaem</i> , 2020, 1, 368-370.	1.0	0
26	Activity of Tyrosine Kinase Inhibitors in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 4804-4804.	1.4	0